A disease may be rare, but its treatment should not be
Catalyst is investing in the science of possibility—discovering, developing, and delivering innovative, life-changing medicines and solutions to transform patients’ lives and address their most important unmet medical needs. It’s all about the company you keep. At Catalyst, we are laser-focused on developing therapies for rare neuromuscular and neurological disorders—we believe this is where we can have the greatest impact on patients’ lives.
Currently, Catalyst has developed amifampridine for Lambert-Eaton myasthenic syndrome (LEMS) and is conducting clinical studies into the following additional therapeutic areas: congenital myasthenic syndromes (CMS), MuSK-positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA).
Catalyst is also developing a highly potent GABA-aminotransferase (GABA-AT) inhibitor for the treatment of infantile spasms, a rare form of debilitating epileptic seizures that presents in infants.